Boston Scientific said most of the new ENERGEN and PUNCTUA devices offer the 4-SITE DF4 connector system option, designed to simplify the implant procedure and comply with international connector standards.
Additionally, nearly all models are compatible with the company’s LATITUDE Patient Management system, which enables physicians to remotely monitor implantable cardiac device patients between on-site office visits.
Professor Joachim Winter, who performed one of the first implants of the ENERGEN ICD at the University Hospital Dusseldorf in Germany, said the devices build on the technological advancements of COGNIS and TELIGEN by providing options to customize therapy for individual patients.
"The small profile, coupled with the 4-SITE connector system, allowed for an easy implant with a less pronounced physical appearance for the patient," Winter said.
The company received CE mark approval for its ENERGEN and PUNCTUA CRT-Ds and ICDs in October 2010.
In the US, they are investigational devices, limited by applicable law to investigational use and not available for sale.
The company expects the Food and Drug Administration approval for the devices in late 2011 or early 2012.
